Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest American Society of Hematology Stories

2013-03-14 12:27:50

WASHINGTON, March 14, 2013 /PRNewswire-USNewswire/ -- Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). HS is an inherited metabolic disease characterized by the lack of a critical...

2013-02-14 12:25:03

WASHINGTON, Feb. 14, 2013 /PRNewswire-USNewswire/ -- While advancements in cancer treatment over the last several decades have improved patient survival rates for certain cancers, some patients remain at risk of developing treatment-related leukemia, according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH). Chemotherapy is often a highly effective treatment for cancer, but certain drugs have also been shown in a range of...

2012-12-20 12:27:14

WASHINGTON, Dec. 20, 2012 /PRNewswire-USNewswire/ -- New research examining the role of race and ethnicity in an individual's decision to become a donor for hematopoietic cell transplantation (HCT) identifies several factors associated with varied participation rates in national donor registries across racial/ethnic groups. Results of this first-of-its-kind study are published online today in Blood, the Journal of the American Society of Hematology (ASH). Hematopoietic cell transplants...

2012-12-11 08:27:15

ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced follow-up findings from an ongoing, open-label, Phase 2, single-agent study suggesting that in patients with relapsed or refractory mantle cell lymphoma (MCL), both those who were bortezomib-naive and bortezomib-exposed, the investigational oral agent ibrutinib (PCI-32765) resulted in high and durable responses and was generally well tolerated. In the study, 111 patients received ibrutinib and 110 were...

2012-12-11 08:27:09

ATLANTA, Dec. 11, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, today announced follow-up findings from an ongoing, open-label, Phase 2, single-agent study showing that in patients with relapsed or refractory mantle cell lymphoma (MCL), the investigational oral agent ibrutinib (PCI-32765) resulted in an overall response rate (ORR) of 68 percent, including a complete response (CR) of 22 percent and a partial response (PR) of 46 percent. The study included both bortezomib-naive...

2012-12-10 16:24:12

EAST HANOVER, N.J., Dec. 10, 2012 /PRNewswire/ -- The latest results from two Phase III clinical trials further establish the benefits of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients and in those with residual disease who switched to Tasigna after long-term treatment with Gleevec. Findings from both studies were presented in oral sessions...

2012-12-10 16:23:57

BOULDER, Colo., Dec. 10, 2012 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced positive data for ARRY-520 and ARRY?614 at the 2012 Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) New results presented at the meeting for ARRY-520 in addition to those described in the abstracts published by ASH in early November included: Overall survival of 19 months and...

2012-12-10 16:44:50

Studies of stem cell biology and transplant approaches presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) illustrate how the use of advanced modeling techniques is optimizing stem cells to treat patients with blood disorders, as well as the potential of enhanced treatment strategies to improve the success rate of hematopoietic stem cell (HSC) transplantation for these patients. Hematopoietic stem cell transplantation is effectively used today as a form...

2012-12-10 16:41:33

Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Hematology (ASH) signal an important step forward in the development of treatment strategies for patients with hard-to-treat leukemia, myeloma, and myelofibrosis. Ongoing discoveries of critical molecular markers, pathways, and other drivers of some of the most difficult-to-treat forms of blood cancer have provided unprecedented opportunities for the...

2012-12-10 16:38:13

Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH). While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators identified how patients' individual genetic makeup influences...